AATS 2013:NSCLC手术切缘增至15mm可降低复发风险

2013-06-25 佚名 EGMN

  明尼阿波利斯——美国胸外科学会(AATS)2013年会上报告的一项针对474例非小细胞肺癌(NSCLC)连续病例数据分析显示,楔形切除术手术切缘宽度增至15 mm可显著降低局部复发风险,但超过15 mm未见额外受益。   波士顿布里格姆妇女医院外科研究员Kamran Mohiuddin博士报告称,与切缘宽度为5 mm相比,切缘宽度为10 mm

  明尼阿波利斯——美国胸外科学会(AATS)2013年会上报告的一项针对474例非小细胞肺癌(NSCLC)连续病例数据分析显示,楔形切除术手术切缘宽度增至15 mm可显著降低局部复发风险,但超过15 mm未见额外受益。

  波士顿布里格姆妇女医院外科研究员Kamran Mohiuddin博士报告称,与切缘宽度为5 mm相比,切缘宽度为10 mm、15 mm和20 mm者的校正后局部复发风险分别降低45%[危险比(HR),0.55]、59%(HR,0.41)和54%(HR,0.46)。“下降趋势变平,表明增加切缘宽度的获益减弱。”

  目前肿瘤<2 cm的NSCLC患者的楔形切除术最佳切缘宽度尚不明确。楔形切除术切缘<1 cm与局部复发高风险相关(Ann. Surg. Oncol. 2007;14:2400-5)。一项多中心前瞻性研究还表明,最佳切缘宽度应大于最大肿瘤直径(Ann. Thorac. Surg. 2004;77:415-20)。

  该医院微创胸外科主任、美国外科医师协会(ACS)会员Scott J. Swanson博士在回答“如果术中发现切缘不够大,基于上述结果是否应采取更为积极的切除方式或肺段切除术”的问题时表示,他们正将上述结果应用于实践,但尚不清楚15 mm是否最佳。

  Swanson博士指出,目前尚不能肯定15 mm切缘是否适合所有患者,但在切除直径≤2 cm的肿瘤时,外科医生记住这一数字是有益的。“与其他研究者提出的切缘宽度与肿瘤直径之比大于1相比,15 mm切缘似乎是一个更好的目标。”

  该分析纳入了2001年1月~2011年8月在该院接受楔形切除术的肿瘤直径≤2 cm、年龄介于21~85岁的所有NSCLC患者资料。切缘宽度(定义为肿瘤至最近吻合器切除边缘的距离)为0.1~0.5 cm、 0.6~1.0 cm、1.1~2.0 cm以及>2 cm的患者比例分别为10%、36%、25.5%和28.5%。

  肿瘤平均直径为1.33 cm,多位于右上叶(36%),电视辅助胸腔镜手术(VATS)占57.5%。患者平均第1秒用力呼气量(FEV1)为79.8%,平均年龄68.5岁。围手术期死亡1例,至少出现1个主要并发症的患者为41例。1年、2年和3年局部复发率分别为5.8%、11.3%和16.8%,中位随访时间为3.9年。

  多变量回归分析显示,增加切缘宽度与局部复发风险降低显著相关,但超过15 mm后额外获益减少(P=0.031)。该分析校正了FEV1、慢性阻塞性肺病、吸烟、糖尿病、肿瘤大小、肿瘤肺叶位置、肿瘤位置血胸、外科医生情况、VATS或开放手术以及淋巴结是否取样等因素。

Wedge resection in NSCLC: Is 15 mm the magic margin?
MINNEAPOLIS – Increasing the surgical margin length up to 15 mm during wedge resection of small lung cancer tumors significantly lowered the risk of local recurrence among 474 consecutive patients.
No additional benefit was observed, however, beyond 15 mm, said Dr. Kamran Mohiuddin, a surgical research fellow at Brigham and Women’s Hospital, Boston.
Compared with a margin length of 5 mm, the adjusted risk of local recurrence was estimated to be 45% lower with a margin length of 10 mm (hazard ratio, 0.55), 59% lower with a 15-mm margin (HR, 0.41), and 54% lower with a 20-mm margin (HR, 0.46)....

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905436, encodeId=d6b81905436cb, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 21:53:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818636, encodeId=4d3b1818636f7, content=<a href='/topic/show?id=747398121ad' target=_blank style='color:#2F92EE;'>#降低复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98121, encryptionId=747398121ad, topicName=降低复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Oct 16 08:53:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080770, encodeId=7da72080e703a, content=<a href='/topic/show?id=897254381a3' target=_blank style='color:#2F92EE;'>#手术切缘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54381, encryptionId=897254381a3, topicName=手术切缘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jan 25 11:53:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068162, encodeId=3aac2068162bc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Sep 10 23:53:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5842, encodeId=f0f15842cd, content=很关键, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jun 29 10:07:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905436, encodeId=d6b81905436cb, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 21:53:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818636, encodeId=4d3b1818636f7, content=<a href='/topic/show?id=747398121ad' target=_blank style='color:#2F92EE;'>#降低复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98121, encryptionId=747398121ad, topicName=降低复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Oct 16 08:53:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080770, encodeId=7da72080e703a, content=<a href='/topic/show?id=897254381a3' target=_blank style='color:#2F92EE;'>#手术切缘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54381, encryptionId=897254381a3, topicName=手术切缘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jan 25 11:53:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068162, encodeId=3aac2068162bc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Sep 10 23:53:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5842, encodeId=f0f15842cd, content=很关键, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jun 29 10:07:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905436, encodeId=d6b81905436cb, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 21:53:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818636, encodeId=4d3b1818636f7, content=<a href='/topic/show?id=747398121ad' target=_blank style='color:#2F92EE;'>#降低复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98121, encryptionId=747398121ad, topicName=降低复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Oct 16 08:53:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080770, encodeId=7da72080e703a, content=<a href='/topic/show?id=897254381a3' target=_blank style='color:#2F92EE;'>#手术切缘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54381, encryptionId=897254381a3, topicName=手术切缘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jan 25 11:53:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068162, encodeId=3aac2068162bc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Sep 10 23:53:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5842, encodeId=f0f15842cd, content=很关键, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jun 29 10:07:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905436, encodeId=d6b81905436cb, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 21:53:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818636, encodeId=4d3b1818636f7, content=<a href='/topic/show?id=747398121ad' target=_blank style='color:#2F92EE;'>#降低复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98121, encryptionId=747398121ad, topicName=降低复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Oct 16 08:53:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080770, encodeId=7da72080e703a, content=<a href='/topic/show?id=897254381a3' target=_blank style='color:#2F92EE;'>#手术切缘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54381, encryptionId=897254381a3, topicName=手术切缘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jan 25 11:53:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068162, encodeId=3aac2068162bc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Sep 10 23:53:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5842, encodeId=f0f15842cd, content=很关键, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jun 29 10:07:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1905436, encodeId=d6b81905436cb, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 21:53:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818636, encodeId=4d3b1818636f7, content=<a href='/topic/show?id=747398121ad' target=_blank style='color:#2F92EE;'>#降低复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98121, encryptionId=747398121ad, topicName=降低复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Oct 16 08:53:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080770, encodeId=7da72080e703a, content=<a href='/topic/show?id=897254381a3' target=_blank style='color:#2F92EE;'>#手术切缘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54381, encryptionId=897254381a3, topicName=手术切缘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jan 25 11:53:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068162, encodeId=3aac2068162bc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Sep 10 23:53:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5842, encodeId=f0f15842cd, content=很关键, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jun 29 10:07:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
    2013-06-29 匿名用户

    很关键

    0

相关资讯

Ann Oncol:老年肺癌患者术后化疗不影响生存质量

  韩国学者的一项研究显示,老年非小细胞肺癌(NSCLC)患者可能存在其它共存病,以及身体机能下降,术后的辅助化疗对老年病人的健康相关生存质量(HRQOL)无显著影响,且治疗前后的HRQOL无显著差别。   该研究于2008年10月到2011年10月期间纳入65岁以上(N=66)和65以下(N=73)的NSCLC患者,比较其化疗后的HRQOL。   结果显示,术后的辅助化疗对老年病人的健康相关

CANCER:在线支持系统可减轻NSCLC患者忧虑

  通过与互联网支持比较,美国学者研究了一种在线支持系统(综合性健康增强支持系统[CHESS])减轻非小细胞肺癌(NSCLC)患者身体症状相关性忧虑的有效性,结果表明,在线支持系统可能会减轻患者身体症状相关性忧虑,但其能否带来生存获益仍需要进一步研究。   该研究纳入285对非正式护理人员和患者,被随机分配到两组,一组接受标准护理和互联网使用的培训与操作(互联网组),另一组接受标准护

ASO:淋巴结跳跃性转移并非胸段食管鳞状细胞癌预后的预测因素

相关研究发现,淋巴结跳跃性转移(NSM)对于非小细胞肺癌具有重要的临床价值,但目前对食管癌NSM的相关研究较为匮乏。为此,我国复旦大学附属肿瘤医院相加庆副教授及付小龙教授等人进行了一项研究,该研究旨在筛选出影响NSM的风险因素,并对NSM在胸段食管鳞状细胞癌中的预后价值做出评价。该研究结果发表于2013年5月18日在线出版的《外科肿瘤学年鉴》(Annals of Surgical Oncology

赛诺菲肺癌药物抗凝血剂III期临床失败

    赛诺菲(Sanofi)2013年6月3日公布了关于实验性肺癌药物iniparib及首个静脉注射型Xa因子抗凝血剂otamixaban的III期临床试验的数据,同时宣布终止这2个药物的临床开发。  Iniparib:  有关iniparib的随机III期ECLIPSE试验,在初诊鳞状非小细胞肺癌(squamous non-small cell lung canc

AATS 2013:亚肺叶与肺叶切除生存率相当

  明尼阿波利斯一项纳入348例在筛查中发现ⅠA期非小细胞肺癌(NSCLC)的患者的队列研究显示,亚肺叶切除术与肺叶切除术具有相似的肺癌生存率和总复发率。   主要研究者、纽约长老会Weill Cornell医疗中心胸外科主任Nasser Altorki医生在美国胸外科学会(AATS)2013年会上报告,经过中位时间73个月的随访,亚肺叶切除组(n=54)和肺叶切除组(n=2

Lung Cancer:EGFR突变与癌症家族史有密切关系

随着表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)如:易瑞沙、特罗凯等广泛的应用,越来越多的研究表明EGFR突变与癌症家族史有着密切的关系。来自同济大学上海肺科医院的周彩存等针对中国地区的患者进行了一项前沿性分析实验,该研究结果发表在2013年5月30日的肺癌(Lung Cancer)杂志。该研究结果表明具有癌症家族史的非小细胞肺癌患者尤其是具有肺癌家族史的患者,具有较高的EGFR突变率。